Drug-Eluting Stents in the Superficial Femoral Artery: The Long and Winding Road

Affiliations

¹ From Divisions of Cardiovascular Medicine (J.R.L.) and Vascular Surgery (M.H.), the Vascular Center, University of California, Davis Medical Center, Sacramento, CA. jrlaird@ucdavis.edu.
² From Divisions of Cardiovascular Medicine (J.R.L.) and Vascular Surgery (M.H.), the Vascular Center, University of California, Davis Medical Center, Sacramento, CA.

Editorial

John R Laird et al. Circulation. 2016.

. 2016 Apr 12;133(15):1435-7.

doi: 10.1161/CIRCULATIONAHA.116.022039. Epub 2016 Mar 11.

¹ From Divisions of Cardiovascular Medicine (J.R.L.) and Vascular Surgery (M.H.), the Vascular Center, University of California, Davis Medical Center, Sacramento, CA. jrlaird@ucdavis.edu.
² From Divisions of Cardiovascular Medicine (J.R.L.) and Vascular Surgery (M.H.), the Vascular Center, University of California, Davis Medical Center, Sacramento, CA.

No abstract available

Keywords: Editorials; angioplasty; drug-eluting stents; peripheral artery disease.

Comment on

Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Machan LS, Snyder SA, O'Leary EE, Ragheb AO, Zeller T; Zilver PTX Investigators. Dake MD, et al. Circulation. 2016 Apr 12;133(15):1472-83; discussion 1483. doi: 10.1161/CIRCULATIONAHA.115.016900. Epub 2016 Mar 11. Circulation. 2016. PMID: 26969758 Free PMC article. Clinical Trial.